Virtus ETF Advisers LLC Acquires 3,061 Shares of Kura Oncology, Inc. (NASDAQ:KURA)

Virtus ETF Advisers LLC lifted its holdings in Kura Oncology, Inc. (NASDAQ:KURA) by 71.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,336 shares of the company’s stock after buying an additional 3,061 shares during the quarter. Virtus ETF Advisers LLC’s holdings in Kura Oncology were worth $64,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in KURA. Barclays PLC raised its holdings in shares of Kura Oncology by 104.5% in the third quarter. Barclays PLC now owns 165,484 shares of the company’s stock valued at $3,234,000 after buying an additional 84,563 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Kura Oncology by 1.5% in the third quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company’s stock valued at $28,687,000 after buying an additional 23,113 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Kura Oncology by 0.8% in the third quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company’s stock valued at $7,997,000 after buying an additional 3,092 shares during the last quarter. Harbor Capital Advisors Inc. raised its holdings in shares of Kura Oncology by 4.4% in the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock valued at $430,000 after buying an additional 2,076 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in Kura Oncology during the 4th quarter worth about $436,000.

Kura Oncology Price Performance

Kura Oncology stock opened at $6.51 on Tuesday. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The business has a 50-day moving average of $6.85 and a 200-day moving average of $9.85. Kura Oncology, Inc. has a 1 year low of $5.41 and a 1 year high of $23.48. The firm has a market capitalization of $525.86 million, a P/E ratio of -2.76 and a beta of 0.83.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.43. The company had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.96 million. On average, equities analysts anticipate that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on KURA. BTIG Research cut Kura Oncology from a “buy” rating to a “neutral” rating in a report on Thursday, February 6th. Cantor Fitzgerald raised Kura Oncology to a “strong-buy” rating in a report on Tuesday, March 4th. Scotiabank dropped their price objective on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. UBS Group dropped their price objective on Kura Oncology from $27.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, March 6th. Finally, StockNews.com raised Kura Oncology from a “hold” rating to a “buy” rating in a report on Friday, April 4th. Three research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $25.50.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.